Showing 5521-5530 of 9555 results for "".
- Positive Results Seen in Phase 3 FMX101 Acne Studyhttps://practicaldermatology.com/news/study-positive-results-see-in-phase-3-fmx101-acne-study/2460088/In patients with moderate to severe acne vulgaris, treatment with FMX101 4% topical minocycline foam is well tolerated and effective for reducing the number of inflammatory lesions, according to results of a randomized trial published in the Journal of the American Academy of Dermatology
- AARS Survey Uncovers Real Impact Of Acne On Young Professionalshttps://practicaldermatology.com/news/aars-survey-uncovers-real-impact-of-acne-on-young-professionals/2460087/Results of a recent American Acne and Rosacea Society (AARS) survey highlight the significant health burden and everyday impact of acne on young professionals. According to the survey of 1,004 men and women between the ages of 22 and 30 conducted by The Harris Poll, many people whose acne persist
- Positive Top-Line Results Seen in Study of Crisaborole for Mild to Moderate AD in Young Childrenhttps://practicaldermatology.com/news/positive-top-line-results-seen-in-study-of-crisaborole-of-for-mild-to-moderate-ad-in-young-children/2460085/Pfizer’s crisaborole ointment (Eucrisa) was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), according to top-line results from a Phase 4 study (CrisADe CARE 1). The data from the trial are supportive of the primary stud
- SENTÉ Names Adelle Walker as Chief Marketing Officerhttps://practicaldermatology.com/news/sente-names-adelle-walker-as-chief-marketing-officer/2460080/SENTÉ® has appointed Adelle Walker Chief Marketing Officer. As Chief Marketing Officer (CMO), she will take an executive leadership role in defining pipeline strategy along with internal and external portfolio planning. Her commercialization leadership will span across all fa
- AbbVie to Acquire Allerganhttps://practicaldermatology.com/news/abbvie-to-acquire-allergan/2460076/AbbVie Inc. and Allergan plc have entered into a definitive transaction agreement under which AbbVie will acquire Al
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary end
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Der